Cargando…

Primary drug resistance of mycobacterium tuberculosis in Shandong, China, 2004–2018

BACKGROUND: Primary drug-resistant tuberculosis (DR-TB) has contributed to a significant health and economic burden on a global scale, especially in China. we sought to estimate epidemiological characteristics of primary DR-TB in China from 2004 to 2018. METHODS: Eleven thousand four hundred sixty-s...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Wan-mei, Li, Yi-fan, Ma, Xiao-bin, Liu, Jin-yue, Tao, Ning-ning, Liu, Yao, Zhang, Qian-yun, Xu, Ting-ting, Li, Shi-jin, Yu, Chun-Bao, Gao, Lei, Cui, Liang-liang, Li, Huai-chen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6798379/
https://www.ncbi.nlm.nih.gov/pubmed/31627757
http://dx.doi.org/10.1186/s12931-019-1199-3
_version_ 1783460025106169856
author Song, Wan-mei
Li, Yi-fan
Ma, Xiao-bin
Liu, Jin-yue
Tao, Ning-ning
Liu, Yao
Zhang, Qian-yun
Xu, Ting-ting
Li, Shi-jin
Yu, Chun-Bao
Gao, Lei
Cui, Liang-liang
Li, Huai-chen
author_facet Song, Wan-mei
Li, Yi-fan
Ma, Xiao-bin
Liu, Jin-yue
Tao, Ning-ning
Liu, Yao
Zhang, Qian-yun
Xu, Ting-ting
Li, Shi-jin
Yu, Chun-Bao
Gao, Lei
Cui, Liang-liang
Li, Huai-chen
author_sort Song, Wan-mei
collection PubMed
description BACKGROUND: Primary drug-resistant tuberculosis (DR-TB) has contributed to a significant health and economic burden on a global scale, especially in China. we sought to estimate epidemiological characteristics of primary DR-TB in China from 2004 to 2018. METHODS: Eleven thousand four hundred sixty-seven newly diagnosed and 1981 retreated TB cases with drug susceptibility data were included. Chi-Square test for trends, linear regression, a joinpoint regression model and temporal trend in proportions of the different resistance patterns were carried out. RESULTS: The proportion of primary DR-TB and mono-resistant TB (MR-TB) in China had reduced by more than 12% since 2004, and were 21.38%, 13.35% in 2018 respectively. Among primary DR-TB cases (2173,18.95%), the percentage of multiresistant TB (MDR-TB, from 5.41 to 17.46%), male (from 77.03 to 84.13%), cavity (from 13.51 to 43.92%), rifampicin(RFP)-resistant TB (from 8.11 to 26.98%), streptomycin(SM)-resistant TB (from 50.00 to 71.43%) increased significantly (P < 0.05). On the contrary, the proportion of female, non-cavity, isoniazide(INH)-resistant TB (from 55.41 to 48.15%) and MR-TB (from 82.43 to 62.43%) decreased significant (P < 0.05). The primary drug resistance rate among female, cavity, smoking, drinking, 15 to 44 year-old TB subgroups increased by 0.16, 6.24, 20.95, 158.85, 31.49%, respectively. The percentage of primary DR-TB, RFP-resistant TB dropped significantly during 2004–2007 in Joinpoint regression model. CONCLUSION: The total rate of drug resistance among new TB cases showed a downward trend in Shandong, China, from 2004 to 2018. Primary drug resistance patterns were shifting from female, non-cavity, INH-resistant TB, and MR-TB groups to male, cavity, RFP/SM-resistant TB, and MDR-TB groups. Considering the rising drug resistance rate among some special population, future control of primary DR-TB in China may require an increased focus on female, cavity, smoking, drinking, or 15 to 44 year-old TB subgroups.
format Online
Article
Text
id pubmed-6798379
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-67983792019-10-21 Primary drug resistance of mycobacterium tuberculosis in Shandong, China, 2004–2018 Song, Wan-mei Li, Yi-fan Ma, Xiao-bin Liu, Jin-yue Tao, Ning-ning Liu, Yao Zhang, Qian-yun Xu, Ting-ting Li, Shi-jin Yu, Chun-Bao Gao, Lei Cui, Liang-liang Li, Huai-chen Respir Res Research BACKGROUND: Primary drug-resistant tuberculosis (DR-TB) has contributed to a significant health and economic burden on a global scale, especially in China. we sought to estimate epidemiological characteristics of primary DR-TB in China from 2004 to 2018. METHODS: Eleven thousand four hundred sixty-seven newly diagnosed and 1981 retreated TB cases with drug susceptibility data were included. Chi-Square test for trends, linear regression, a joinpoint regression model and temporal trend in proportions of the different resistance patterns were carried out. RESULTS: The proportion of primary DR-TB and mono-resistant TB (MR-TB) in China had reduced by more than 12% since 2004, and were 21.38%, 13.35% in 2018 respectively. Among primary DR-TB cases (2173,18.95%), the percentage of multiresistant TB (MDR-TB, from 5.41 to 17.46%), male (from 77.03 to 84.13%), cavity (from 13.51 to 43.92%), rifampicin(RFP)-resistant TB (from 8.11 to 26.98%), streptomycin(SM)-resistant TB (from 50.00 to 71.43%) increased significantly (P < 0.05). On the contrary, the proportion of female, non-cavity, isoniazide(INH)-resistant TB (from 55.41 to 48.15%) and MR-TB (from 82.43 to 62.43%) decreased significant (P < 0.05). The primary drug resistance rate among female, cavity, smoking, drinking, 15 to 44 year-old TB subgroups increased by 0.16, 6.24, 20.95, 158.85, 31.49%, respectively. The percentage of primary DR-TB, RFP-resistant TB dropped significantly during 2004–2007 in Joinpoint regression model. CONCLUSION: The total rate of drug resistance among new TB cases showed a downward trend in Shandong, China, from 2004 to 2018. Primary drug resistance patterns were shifting from female, non-cavity, INH-resistant TB, and MR-TB groups to male, cavity, RFP/SM-resistant TB, and MDR-TB groups. Considering the rising drug resistance rate among some special population, future control of primary DR-TB in China may require an increased focus on female, cavity, smoking, drinking, or 15 to 44 year-old TB subgroups. BioMed Central 2019-10-18 2019 /pmc/articles/PMC6798379/ /pubmed/31627757 http://dx.doi.org/10.1186/s12931-019-1199-3 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Song, Wan-mei
Li, Yi-fan
Ma, Xiao-bin
Liu, Jin-yue
Tao, Ning-ning
Liu, Yao
Zhang, Qian-yun
Xu, Ting-ting
Li, Shi-jin
Yu, Chun-Bao
Gao, Lei
Cui, Liang-liang
Li, Huai-chen
Primary drug resistance of mycobacterium tuberculosis in Shandong, China, 2004–2018
title Primary drug resistance of mycobacterium tuberculosis in Shandong, China, 2004–2018
title_full Primary drug resistance of mycobacterium tuberculosis in Shandong, China, 2004–2018
title_fullStr Primary drug resistance of mycobacterium tuberculosis in Shandong, China, 2004–2018
title_full_unstemmed Primary drug resistance of mycobacterium tuberculosis in Shandong, China, 2004–2018
title_short Primary drug resistance of mycobacterium tuberculosis in Shandong, China, 2004–2018
title_sort primary drug resistance of mycobacterium tuberculosis in shandong, china, 2004–2018
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6798379/
https://www.ncbi.nlm.nih.gov/pubmed/31627757
http://dx.doi.org/10.1186/s12931-019-1199-3
work_keys_str_mv AT songwanmei primarydrugresistanceofmycobacteriumtuberculosisinshandongchina20042018
AT liyifan primarydrugresistanceofmycobacteriumtuberculosisinshandongchina20042018
AT maxiaobin primarydrugresistanceofmycobacteriumtuberculosisinshandongchina20042018
AT liujinyue primarydrugresistanceofmycobacteriumtuberculosisinshandongchina20042018
AT taoningning primarydrugresistanceofmycobacteriumtuberculosisinshandongchina20042018
AT liuyao primarydrugresistanceofmycobacteriumtuberculosisinshandongchina20042018
AT zhangqianyun primarydrugresistanceofmycobacteriumtuberculosisinshandongchina20042018
AT xutingting primarydrugresistanceofmycobacteriumtuberculosisinshandongchina20042018
AT lishijin primarydrugresistanceofmycobacteriumtuberculosisinshandongchina20042018
AT yuchunbao primarydrugresistanceofmycobacteriumtuberculosisinshandongchina20042018
AT gaolei primarydrugresistanceofmycobacteriumtuberculosisinshandongchina20042018
AT cuiliangliang primarydrugresistanceofmycobacteriumtuberculosisinshandongchina20042018
AT lihuaichen primarydrugresistanceofmycobacteriumtuberculosisinshandongchina20042018